The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure.
Administration, Oral
Adult
Aged
Anti-Ulcer Agents
/ administration & dosage
Antineoplastic Agents
/ administration & dosage
Drug Administration Schedule
Drug Interactions
Eating
Female
Humans
Indazoles
/ administration & dosage
Male
Middle Aged
Neoplasms
/ drug therapy
Pyrimidines
/ administration & dosage
Sulfonamides
/ administration & dosage
drug-drug interaction
gastric acid-suppressive agents
omeprazole
pantoprazole
pazopanib
pharmacokinetics
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
revised:
16
11
2020
received:
28
09
2020
accepted:
17
12
2020
pubmed:
12
1
2021
medline:
14
9
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
Co-treatment with gastric acid suppressants (GAS) in patients taking anticancer drugs that exhibit pH-dependant absorption may lead to decreased drug exposure and may hamper drug efficacy. In our study, we investigated whether a 1-hour time interval between subsequent intake of pazopanib and GAS could mitigate this negative effect on drug exposure. We performed an observational study in which we collected the first steady-state pazopanib trough concentration (C
Identifiants
pubmed: 33428771
doi: 10.1002/ijc.33469
pmc: PMC8048885
doi:
Substances chimiques
Anti-Ulcer Agents
0
Antineoplastic Agents
0
Indazoles
0
Pyrimidines
0
Sulfonamides
0
pazopanib
7RN5DR86CK
Banques de données
ClinicalTrials.gov
['NCT02138526']
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2799-2806Informations de copyright
© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Eur J Clin Pharmacol. 2020 Sep;76(9):1273-1280
pubmed: 32474662
Int J Pharm. 2018 Jun 10;544(1):181-190
pubmed: 29680279
Clin Pharmacokinet. 2017 Jul;56(7):683-688
pubmed: 28101705
Br J Clin Pharmacol. 2017 Oct;83(10):2195-2204
pubmed: 28500677
J Biol Chem. 1997 Sep 5;272(36):22438-46
pubmed: 9278394
Clin Pharmacokinet. 2014 Feb;53(2):185-96
pubmed: 24135988
Mol Pharm. 2013 Nov 4;10(11):4055-62
pubmed: 24044612
Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71
pubmed: 19967539
J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Oct 15;937:33-43
pubmed: 24013127
Br J Clin Pharmacol. 2008 May;65(5):752-60
pubmed: 18241283
Drug Saf. 2014 Apr;37(4):201-11
pubmed: 24550106
Br J Cancer. 2014 Nov 11;111(10):1909-16
pubmed: 25349968
Clin Cancer Res. 2019 Mar 1;25(5):1479-1485
pubmed: 30765389
Drug Metab Dispos. 2004 Aug;32(8):821-7
pubmed: 15258107
Clin Pharmacol Ther. 2006 Jan;79(1):103-13
pubmed: 16413245
Clin Pharmacol Ther. 2010 Dec;88(6):818-23
pubmed: 20980999
Cancer Chemother Pharmacol. 2013 Jun;71(6):1635-43
pubmed: 23636448
Clin Pharmacol Ther. 2013 Sep;94(3):317-23
pubmed: 23698643
Biomed Chromatogr. 2017 Nov;31(11):
pubmed: 28370076
Mol Cancer Ther. 2007 Jul;6(7):2012-21
pubmed: 17620431
Drugs. 2003;63(24):2739-54
pubmed: 14664653
Clin Pharmacol Ther. 2019 Nov;106(5):1076-1082
pubmed: 31125423
Clin Pharmacol Ther. 1992 Aug;52(2):170-80
pubmed: 1505152
Ther Drug Monit. 2009 Oct;31(5):579-84
pubmed: 19730279
Pharmacotherapy. 1993 Jan-Feb;13(1):3-9
pubmed: 8437966
Lancet Oncol. 2013 Nov;14(12):1233-42
pubmed: 24140184
Eur J Pharm Sci. 2019 Jun 15;134:31-59
pubmed: 30974173
J Clin Oncol. 2009 Jul 1;27(19):3141-7
pubmed: 19451435
Cancer Chemother Pharmacol. 2017 Dec;80(6):1171-1178
pubmed: 29051995
Xenobiotica. 2013 May;43(5):443-53
pubmed: 23548165
Clin Cancer Res. 2009 Jun 15;15(12):4220-7
pubmed: 19509175
Oncologist. 2018 Jun;23(6):686-692
pubmed: 29487220
Am J Gastroenterol. 2003 Dec;98(12):2616-20
pubmed: 14687806
Int J Cancer. 2021 Jun 1;148(11):2799-2806
pubmed: 33428771
Eur Urol. 2019 Aug;76(2):151-156
pubmed: 31151678